Rapport Therapeutics, Inc.
NNASDAQ:RAPPCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Abraham N. Ceesay
- Full Time Employees
- 84
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 99 High Street Boston MA United States 02110
- IPO Date
- Jun 7, 2024
- CIK
- 0002012593
- Website
- rapportrx.com
- Similar Companies
- Business
- Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines targeting central nervous system (CNS) disorders through its proprietary RAP technology platform. The company advances a pipeline including lead candidate RAP-219, a TARPγ8-selective AMPAR inhibitor for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain; RAP-199, a differentiated TARPγ8-targeted molecule; and discovery-stage nicotinic acetylcholine receptor (nAChR) programs comprising α6 nAChR modulators for chronic pain and α9α10 nAChR modulators for hearing disorders. Founded in 2022 and headquartered in Boston, Massachusetts, with additional operations in San Diego, California, Rapport targets patients with neurological conditions underserved by broad-acting therapies. Recent developments include positive topline results from a Phase 2a trial of RAP-219 in focal onset seizures announced in September 2025, demonstrating a 78% median seizure reduction; ongoing Phase 2 enrollment in bipolar mania with results expected in first-half 2027; plans for an FDA end-of-Phase 2 meeting by year-end 2025 and two Phase 3 pivotal trials in focal onset seizures starting third-quarter 2026; and approximately $269 million in net proceeds from a recent public offering, extending cash runway into second-half 2029. The company, formerly Precision Neuroscience NewCo, Inc., went public on Nasdaq in June 2024 following a $150 million Series B financing in 2023 led by Cormorant Asset Management.
Company News
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Why Is Rapport Therapeutics Stock Trading Higher Today?
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP
Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP
Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Time to Buy?
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference